ADIMMUNE CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.05 TWD | -0.55% |
|
-5.09% | -18.40% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.40% | 350M | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +55.83% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +4.94% | 8.75B |
- Stock Market
- Equities
- 4142 Stock
- News Adimmune Corporation
- Adimmune : to Provide Key Ingredient of Quadrivalent Flu Vaccine to Russian Pharma Company
